Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23091747 | 0.82 | NAMPT (0.51) | PDE4BNAMPTRORCKDM4EGPR119 | |
| SCHEMBL20607546 | 0.79 | RORC (0.48) | PDE4BNAMPTRORCKDM4EGPR119 | |
| SCHEMBL17736163 | 0.79 | GPR119 (0.53) | PDE4BNAMPTRORCKDM4EGPR119 | |
| SCHEMBL25252948 | 0.79 | NAMPT (0.38) | NAMPT | |
| SCHEMBL20757468 | 0.78 | MEN1 (0.57) | PDE4BNAMPTRORCKDM4E | |
| SCHEMBL21381667 | 0.78 | RORC (0.53) | PDE4BNAMPTRORCKDM4E | |
| SCHEMBL23149076 | 0.78 | KDM4E (0.49) | PDE4BNAMPTRORCKDM4EGPR119 | |
| SCHEMBL10289613 | 0.78 | NR1H2 (0.49) | PDE4BNAMPTRORCKDM4EGPR119 | |
| SCHEMBL15187965 | 0.78 | RORC (0.56) | PDE4BNAMPTRORCKDM4E | |
| SCHEMBL30712261 | 0.78 | RORC (0.50) | PDE4BNAMPTRORCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | PDE4B 1481/4885NAMPT 1819/4885RORC 1489/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | PDE4B 1481/4885NAMPT 1819/4885RORC 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.